Stocks Health care ZNTL
NASDAQ · Health careZentalis Pharmaceuticals, Inc. (ZNTL)
It posted a net loss of $141.7M. In fiscal 2025 capital spending exceeded operating cash flow by $125.2M. At September 30, 2026 it held $24M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Zentalis Pharmaceuticals, Inc.
- Net worth
- Zentalis Pharmaceuticals, Inc. has a market value (market cap) of $170.4M at the latest share price, and shareholders' equity of $204.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $137.1M.
- Cash flow
- In fiscal 2025 operations used $125.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Zentalis Pharmaceuticals, Inc.'s next report is expected around March 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Zentalis Pharmaceuticals, Inc. does
Zentalis Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ZNTL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$137.1M | -$1.91 | -$125.2M |
| 2024 | $67.4M | -$165.8M | -$2.33 | -$171.1M |
| 2023 | $0 | -$292.2M | -$4.47 | -$208.4M |
| 2022 | $0 | -$236.8M | -$4.48 | -$166.3M |
| 2021 | n/a | -$158.7M | -$3.72 | -$160.2M |
| 2020 | n/a | -$117.8M | -$4.19 | -$87.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Zentalis Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 19, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Other event 8-K
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026
- July 30, 2026Passive stake (5% or more) SCHEDULE 13G
- June 18, 2026
Insider trades
What the people running Zentalis Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $15.2M worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 30, 2026 | Bruns IngmarChief Medical Officer | Received as pay | 9,727 | $21.2K |
| August 14, 2026 | Walters Group10% owner | Bought | 4,335,000 | $15.2M |
| June 16, 2026 | Myers Scott DunsethDirector | Received as pay | 57,100 | - |
| June 16, 2026 | Walker Luke NathanielDirector | Received as pay | 57,100 | - |
| June 16, 2026 | Johnson David MichaelDirector | Received as pay | 57,100 | - |
| June 16, 2026 | Skvarka JanDirector | Received as pay | 57,100 | - |
| June 16, 2026 | Kariuki EnochDirector | Received as pay | 57,100 | - |
| May 26, 2026 | Campbell ShannonDirector | Received as pay | 114,200 | - |
Who owns ZNTL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Walters William T13G, passive with 2 related filers | 18.8% | August 19, 2026 |
| Andrew J. Schwab13G, passive with 6 related filers | 6.4% | December 30, 2025 |
| Squadron Master Fund LP13G, passive with 3 related filers | 5.1% | March 3, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 114 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| 5AM Venture Management, LLC | 3,947,913 | 0 |
| BlackRock, Inc. | 3,753,525 | +2,483,688 |
| Squadron Capital Management LLC | 3,700,000 | +69,000 |
| Two Sigma Investments, LP | 3,024,936 | +68,410 |
| Vanguard Capital Management LLC | 2,835,669 | +524,962 |
| Citadel Advisors LLC | 2,298,403 | +566,320 |
| Renaissance Technologies LLC | 1,609,078 | -329,067 |
| Opaleye Management Inc. | 1,412,656 | 0 |
| Orbimed Advisors LLC | 1,390,576 | new |
| Decheng Capital LLC | 1,323,327 | 0 |
| Geode Capital Management, LLC | 1,284,117 | +663,081 |
| Bank of America Corp | 1,114,650 | -17,644 |
| Ishara Investments LP | 1,025,000 | -205,000 |
| Primecap Management Co | 957,420 | 0 |
| Soleus Capital Management, L.P. | 950,000 | new |
| State Street Corp | 887,416 | +637,726 |
| Vanguard Portfolio Management LLC | 808,548 | +447,948 |
| Pfizer Inc | 953,834 | 0 |
| Connor, Clark & Lunn Investment Management Ltd. | 758,033 | -33,968 |
| Millennium Management LLC | 664,281 | -625,541 |
Insiders
11 insiders reported holding 26,051,363 shares in total, about $46.9M at the last price.
| Holder | Shares |
|---|---|
| Walters Group10% owner | 17,844,973 |
| Matrix Capital Management Company, LP10% owner | 6,459,9736,459,973 held indirectly |
| Myers Scott DunsethDirector | 395,895 |
| Johnson David MichaelDirector | 307,521 |
| Skvarka JanDirector | 264,254 |
| Walker Luke NathanielDirector | 201,384 |
| Kariuki EnochDirector | 194,465 |
| Vultaggio VincentPAO and PFO | 146,506 |
| Campbell ShannonDirector | 114,200 |
| Eastland Julia MarieCEO & President, Director | 79,133 |
Questions about ZNTL
What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as ZNTL. Its shares trade on NASDAQ under the ticker ZNTL.
What is Zentalis Pharmaceuticals, Inc.'s net worth?
Zentalis Pharmaceuticals, Inc. has a market value (market cap) of $170.4M at the latest share price, and shareholders' equity of $204.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Zentalis Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $141.7M.
When did Zentalis Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Zentalis Pharmaceuticals, Inc.'s next earnings report?
Zentalis Pharmaceuticals, Inc.'s next report is expected around March 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ZNTL with
Follow ZNTL
Get an email when Zentalis Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Zentalis Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.